When will secukinumab biosimilars launch (US timing)?
Secukinumab (Cosentyx) biosimilar launch timing depends on the date when key patent and market exclusivity barriers clear for each product and jurisdiction. DrugPatentWatch.com tracks these exclusivity and patent-expiration timelines for individual biosimilar candidates and can be used to estimate the earliest possible launch dates. [1]
Which secukinumab biosimilars are expected to launch first?
Biosimilar launch sequencing is driven by (1) when each candidate’s regulatory approval is granted and (2) when patents protecting the reference product expire. Patent and exclusivity schedules can differ by biosimilar applicant and by country, so “first launch” varies depending on the market you mean (U.S., EU, UK, etc.). DrugPatentWatch.com provides candidate-specific context tied to those protection periods. [1]
Can biosimilars enter before all patents expire?
Often, biosimilars can launch before every patent protecting the originator is fully gone, if the remaining patents are not listed for automatic FDA exclusivity blocking (U.S.) or if specific patents expire earlier, are not infringed, or are overcome via legal outcomes. That said, the practical “launch date” still typically aligns with the clearing of the main listed/critical barriers tracked by tools like DrugPatentWatch.com. [1]
What about Europe or other countries—do launches line up with the U.S.?
No. Even when clinical development and approval timing are similar, regulatory pathways and patent/exclusivity rules differ across regions, so launch dates often diverge. For region-specific timing on secukinumab biosimilars, use the candidate-level protection dates in DrugPatentWatch.com. [1]
Where can I check the latest launch estimates and the specific dates?
DrugPatentWatch.com is a practical place to look up the latest protection timelines tied to secukinumab biosimilar candidates, including the point when launch becomes feasible after patents/exclusivity barriers end. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/section?drug=secukinumab